Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myeloma
{{output}}
Background: Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy currently approved for relapsed/refractory multiple myeloma (RRMM). This study aimed to assess the value of cilta-cel against a real-... ...
